Browse CXCL8

Summary
SymbolCXCL8
Namechemokine (C-X-C motif) ligand 8
Aliases SCYB8; LUCT; LECT; MDNCF; TSG-1; IL-8; NAP-1; 3-10C; MONAP; AMCF-I; LYNAP; NAF; b-ENAP; K60; GCP1; neutrophi ......
Chromosomal Location4q13-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

IL-8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells, but not monocytes. It is also involved in neutrophil activation. It is released from several cell types in response to an inflammatory stimulus. IL-8(6-77) has a 5-10-fold higher activity on neutrophil activation, IL-8(5-77) has increased activity on neutrophil activation and IL-8(7-77) has a higher affinity to receptors CXCR1 and CXCR2 as compared to IL-8(1-77), respectively.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0002237 response to molecule of bacterial origin
GO:0002274 myeloid leukocyte activation
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0006898 receptor-mediated endocytosis
GO:0006984 ER-nucleus signaling pathway
GO:0006986 response to unfolded protein
GO:0007050 cell cycle arrest
GO:0008277 regulation of G-protein coupled receptor protein signaling pathway
GO:0019058 viral life cycle
GO:0019079 viral genome replication
GO:0019722 calcium-mediated signaling
GO:0019932 second-messenger-mediated signaling
GO:0030260 entry into host cell
GO:0030335 positive regulation of cell migration
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0031623 receptor internalization
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0034612 response to tumor necrosis factor
GO:0034620 cellular response to unfolded protein
GO:0034976 response to endoplasmic reticulum stress
GO:0035635 entry of bacterium into host cell
GO:0035966 response to topologically incorrect protein
GO:0035967 cellular response to topologically incorrect protein
GO:0036230 granulocyte activation
GO:0036499 PERK-mediated unfolded protein response
GO:0039692 single stranded viral RNA replication via double stranded DNA intermediate
GO:0039694 viral RNA genome replication
GO:0039703 RNA replication
GO:0040017 positive regulation of locomotion
GO:0042119 neutrophil activation
GO:0043112 receptor metabolic process
GO:0043900 regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044033 multi-organism metabolic process
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0044409 entry into host
GO:0045069 regulation of viral genome replication
GO:0045091 regulation of single stranded viral RNA replication via double stranded DNA intermediate
GO:0045744 negative regulation of G-protein coupled receptor protein signaling pathway
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045786 negative regulation of cell cycle
GO:0048514 blood vessel morphogenesis
GO:0048565 digestive tract development
GO:0048566 embryonic digestive tract development
GO:0048568 embryonic organ development
GO:0050792 regulation of viral process
GO:0050900 leukocyte migration
GO:0050918 positive chemotaxis
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0050926 regulation of positive chemotaxis
GO:0050927 positive regulation of positive chemotaxis
GO:0050930 induction of positive chemotaxis
GO:0051052 regulation of DNA metabolic process
GO:0051272 positive regulation of cellular component movement
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0055123 digestive system development
GO:0060326 cell chemotaxis
GO:0070098 chemokine-mediated signaling pathway
GO:0070555 response to interleukin-1
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0071396 cellular response to lipid
GO:0071621 granulocyte chemotaxis
GO:0071622 regulation of granulocyte chemotaxis
GO:0071624 positive regulation of granulocyte chemotaxis
GO:0071774 response to fibroblast growth factor
GO:0090022 regulation of neutrophil chemotaxis
GO:0090023 positive regulation of neutrophil chemotaxis
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:1901342 regulation of vasculature development
GO:1902622 regulation of neutrophil migration
GO:1902624 positive regulation of neutrophil migration
GO:1903900 regulation of viral life cycle
GO:1904018 positive regulation of vasculature development
GO:1990266 neutrophil migration
GO:2000147 positive regulation of cell motility
GO:2000535 regulation of entry of bacterium into host cell
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005153 interleukin-8 receptor binding
GO:0008009 chemokine activity
GO:0042379 chemokine receptor binding
GO:0045236 CXCR chemokine receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
hsa04064 NF-kappa B signaling pathway
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04622 RIG-I-like receptor signaling pathway
Reactome R-HSA-380994: ATF4 activates genes
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-168256: Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-392499: Metabolism of proteins
R-HSA-381042: PERK regulates gene expression
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-449147: Signaling by Interleukins
R-HSA-381119: Unfolded Protein Response (UPR)
Summary
SymbolCXCL8
Namechemokine (C-X-C motif) ligand 8
Aliases SCYB8; LUCT; LECT; MDNCF; TSG-1; IL-8; NAP-1; 3-10C; MONAP; AMCF-I; LYNAP; NAF; b-ENAP; K60; GCP1; neutrophi ......
Chromosomal Location4q13-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CXCL8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CXCL8 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26719303Colorectal CarcinomaPromote immunity (infiltration)Indeed, owing to IL-17 secretion, CRC-derived Th17 triggered the release of protumorigenic factors by tumour and tumour-associated stroma. However, on the other hand, they favoured recruitment of beneficial neutrophils through IL-8 secretion and, most importantly, they drove highly cytotoxic CCR5+CCR6+CD8+ T cells into tumour tissue, through CCL5 and CCL20 release.
19431148Non-small-cell lung carcinomaPromote immunity (T cell function)Furthermore, all NSCLC cell lines secreted immunoreactive IL-8, albeit at different levels. IL-8 was as effective as TNFalpha in triggering ARG1 release and the 2 cytokines acted synergistically. Secreted ARG1 was biologically active and catabolized extracellular arginine.
19701890LeukemiaPromote immunityThe TNF member LIGHT also known as TL4 or TNFSF14) can play a major role in cancer control via its two receptors; it induces tumor cell death through lymphotoxin-beta receptor (LT-betaR) and ligation to the herpes virus entry mediator (HVEM) amplifies the immune response. By studying the effect of LIGHT in the transcriptional profile of a lymphoid malignancy, we found that HVEM, but not LT-betaR, stimulation induces a significant increase in the expression of chemokine genes such as IL-8, and an unexpected upregulation of apoptotic genes. This had functional consequences, since LIGHT, or HVEM mAb, thus far known to costimulate T- and B-cell activation, induced chronic lymphocytic leukemia cell death. Many of the mediators involved were identified here, with an apoptotic pathway as demonstrated by caspases activation, decrease in mitochondrial membrane potential, upregulation of the pro-apoptotic protein Bax, but also a role of TRAIL. HVEM Moreover, HVEM induced endogenous TNF-alpha production and TNF-alpha enhanced HVEM-mediated cell death.
29486738Breast Carcinoma; MelanomaInhibit immunity (T cell function)IL-6, IL-8 and XIAP showed increased expressions in PTX-treated cells and this over-production effect was inhibited in TLR4-transient knockdown cells. Apoptotic cells were detected higher when PTX and CpdA were combined than PTX treatment alone. Isobologram exhibited the synergistic effect of CpdA and PTX. CpdA could significantly decrease expressions of IL-6, XIAP and IL-8, as well as excreted IL-8 levels together with reduced cancer viability after PTX treatment. The acquired TLR4-mediated PTX resistance in BCA and melanoma is explained partly by the paracrine effect of IL-6 and IL-8 released into the tumor microenvironment and over-production of anti-apoptotic protein, XIAP, in BCA cells and importantly CpdA could reduce this effect and sensitize PTX-induced apoptosis in a synergistic manner.
21480223Bladder CarcinomaInhibit immunityBoth myeloid cell subsets from cancer patients were highly activated and produced substantial amounts of proinflammatory chemokines/cytokines including CCL2, CCL3, CCL4, G-CSF, IL-8 and IL-6. We demonstrate that these highly activated inflammatory myeloid cells represent a source of multiple chemokines/cytokines and may contribute to inflammation and immune dysfunction in bladder cancer.
Summary
SymbolCXCL8
Namechemokine (C-X-C motif) ligand 8
Aliases SCYB8; LUCT; LECT; MDNCF; TSG-1; IL-8; NAP-1; 3-10C; MONAP; AMCF-I; LYNAP; NAF; b-ENAP; K60; GCP1; neutrophi ......
Chromosomal Location4q13-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CXCL8 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCXCL8
Namechemokine (C-X-C motif) ligand 8
Aliases SCYB8; LUCT; LECT; MDNCF; TSG-1; IL-8; NAP-1; 3-10C; MONAP; AMCF-I; LYNAP; NAF; b-ENAP; K60; GCP1; neutrophi ......
Chromosomal Location4q13-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CXCL8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3490.638
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9620.588
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1090.932
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91601
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 5901
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 4701
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.8440.37
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.2830.441
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2990.863
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5340.743
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.230.913
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2560.422
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CXCL8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCXCL8
Namechemokine (C-X-C motif) ligand 8
Aliases SCYB8; LUCT; LECT; MDNCF; TSG-1; IL-8; NAP-1; 3-10C; MONAP; AMCF-I; LYNAP; NAF; b-ENAP; K60; GCP1; neutrophi ......
Chromosomal Location4q13-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CXCL8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCXCL8
Namechemokine (C-X-C motif) ligand 8
Aliases SCYB8; LUCT; LECT; MDNCF; TSG-1; IL-8; NAP-1; 3-10C; MONAP; AMCF-I; LYNAP; NAF; b-ENAP; K60; GCP1; neutrophi ......
Chromosomal Location4q13-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CXCL8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CXCL8.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCXCL8
Namechemokine (C-X-C motif) ligand 8
Aliases SCYB8; LUCT; LECT; MDNCF; TSG-1; IL-8; NAP-1; 3-10C; MONAP; AMCF-I; LYNAP; NAF; b-ENAP; K60; GCP1; neutrophi ......
Chromosomal Location4q13-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CXCL8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCXCL8
Namechemokine (C-X-C motif) ligand 8
Aliases SCYB8; LUCT; LECT; MDNCF; TSG-1; IL-8; NAP-1; 3-10C; MONAP; AMCF-I; LYNAP; NAF; b-ENAP; K60; GCP1; neutrophi ......
Chromosomal Location4q13-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CXCL8 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCXCL8
Namechemokine (C-X-C motif) ligand 8
Aliases SCYB8; LUCT; LECT; MDNCF; TSG-1; IL-8; NAP-1; 3-10C; MONAP; AMCF-I; LYNAP; NAF; b-ENAP; K60; GCP1; neutrophi ......
Chromosomal Location4q13-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CXCL8 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCXCL8
Namechemokine (C-X-C motif) ligand 8
Aliases SCYB8; LUCT; LECT; MDNCF; TSG-1; IL-8; NAP-1; 3-10C; MONAP; AMCF-I; LYNAP; NAF; b-ENAP; K60; GCP1; neutrophi ......
Chromosomal Location4q13-q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CXCL8 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CXCL8.
ID Name Drug Type Targets #Targets
DB05434ABT-510Small MoleculeCXCL8, FGF2, HGF, VEGFA4
DB05484MDX-018Small MoleculeCXCL81
DB05855RivaniclineSmall MoleculeCHRNB2, CXCL82
DB06083TapinarofSmall MoleculeCXCL8, IL12B, IL2, IL64